Polarization risk in China’s insurance industry is rising, with intensifying capital pressure on small and mid-sized insurers

Overview

This report discusses the structural divergence in China’s insurance industry under capital constraints, distribution reform, rising risk management requirements, and uncertainty over shareholder returns. J.P. Morgan believes that while long-term industry penetration still has support, capital markets are unwilling to continue funding small and mid-sized insurers with insufficient returns and high capital consumption, and market polarization across both life and non-life insurance may accelerate over the medium term.

Core views

The core view is that the insurance industry has already formed an oligopolistic structure at the top, while smaller participants remain highly fragmented; capital strength, solvency, SARMRA scores, IRR ratings, and distribution capabilities will determine competitive outcomes. Large insurers have stronger advantages through more stable capital buffers, distribution resources, data, and reinsurance capabilities; small and mid-sized insurers may gradually lose share due to difficulties in raising capital, insufficient internal profitability, and low visibility on shareholder returns. Regional banks are also showing similar divergence, with the market favoring high-quality regional banks with stable asset quality and credible growth stories.

Analysis framework

By covering 163 insurance companies and combining analysis of the number of industry licenses, premium scale, market share, core solvency, SARMRA scores, IRR ratings, underwriting profitability, distribution structure, and shareholder return policies, the report assesses the concentration trend in China’s insurance industry and its investment implications.

Methodology notes

• Solvency analysisCore solvency adequacy ratio

  Measures the core capital buffer of an insurer to absorb risk and support expansion of new business.

  The report notes that large listed life insurers generally maintain core solvency ratios above 100%, while some unlisted life insurers are below 100%, and even below 70%, indicating significant pressure to replenish capital.

• Risk management assessmentSARMRA

  Solvency Aligned Risk Management Requirements and Assessment, a qualitative regulatory score for insurers’ enterprise-wide risk management capabilities.

  SARMRA has a maximum score of 100, with 80 as a key threshold. A score below 80 increases the minimum capital requirement for operational risk, while a score below 70 usually indicates clear deficiencies in risk governance.

• Regulatory risk ratingIRR

  Insurance Risk Rating, a quarterly comprehensive risk rating across eight grades: AAA, AA, A, BBB, BB, B, C, and D.

  IRR integrates solvency, SARMRA, corporate governance, liquidity, compliance, and potential operational risks. A C or D rating triggers regulatory corrective measures, including restrictions on new business, distribution channels, and investment activities.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Taiping Insurance - H(0966.HK)

  Potential beneficiary

  Strengths

  Mature participating insurance business, relatively balanced capital allocation, and ability to absorb business flows migrating amid industry divergence.

  Weaknesses

  Still operating in an environment of industry-wide capital consumption and intensifying distribution competition.

  Comparison

  Has stronger scale and operating foundations than small and mid-sized life insurers with weaker capital positions.

  Risks

  If new business growth in the industry falls short of expectations or capital market volatility intensifies, earnings and dividend visibility may still come under pressure.

• China Reinsurance Group - H(1508.HK)

  Potential beneficiary

  Strengths

  Capital pressure on small and mid-sized insurers may increase demand for financial reinsurance and reinsurance coverage.

  Weaknesses

  Rated N, and regulators are tightening rules on financial reinsurance.

  Comparison

  Compared with directly underwriting small and mid-sized insurers, its benefit path comes more from expanded reinsurance demand.

  Risks

  Tighter regulation, slower-than-expected realization of reinsurance demand, or rising underwriting risk.

• Bank of Ningbo - A(002142.SZ)

  Top regional bank pick

  Strengths

  Good FY26 fee-income growth potential, stable asset quality, and a more credible growth story.

  Weaknesses

  Regional banks as a group are still affected by investor concerns over capital, asset quality, and dividend sustainability at small and mid-sized banks.

  Comparison

  More favored than small and mid-sized regional banks offering high dividends but with questionable growth and dividend reliability.

  Risks

  Regional economic conditions, credit costs, and regulatory consolidation pressure may affect valuation.

• Large Chinese insurance companies

  Group of structural winners

  Strengths

  Thicker capital buffers, stronger distribution resources, more stable SARMRA and IRR performance, and more transparent dividend frameworks.

  Weaknesses

  Leading life insurers’ market share has declined somewhat in recent years, and they still need to cope with product and distribution reform.

  Comparison

  Better able than small and mid-sized insurers to absorb capital consumption and macro risks.

  Risks

  Interest rates, capital market volatility, distribution reform, and weaker-than-expected new business growth.

• Small and mid-sized insurance companies

  Under-pressure group

  Strengths

  Some companies benefit in the short term from the expansion of participating insurance products.

  Weaknesses

  Thin capital buffers, weak brands and distribution, insufficient internal profitability, low risk management scores, and poor visibility on shareholder returns.

  Comparison

  More likely than market leaders to fall into a negative cycle between capital replenishment and business expansion.

  Risks

  Capital calls, loss of market share, regulatory rating downgrades, business contraction, and industry consolidation.

Key data

• Insurance company coverage163 companiesIncluding 75 life insurers and 88 non-life insurers.
• Number of insurance legal entities in China238As of June 2025, a sharp increase from 97 in December 2005.
• China total premiums in 2025Rmb6.1T / US$870BMore than tripled from 2005.
• Insurance penetration rate4.4%Premiums as a share of GDP in 2025, above 3.5% in 2015.
• Top five life insurers' share45%Shows top-end concentration, though leading life insurers’ share has declined somewhat in recent years.
• Top five non-life insurers' share68%Top-end share in non-life insurance is relatively stable.
• Share of life insurer sample with solvency below 100%About 28%Equivalent to 17 unlisted life insurers.
• Share of non-life insurers with underwriting lossesAbout 55%About 55% of non-life insurers reported underwriting losses in 2025.
• Companies with SARMRA below 7016 companies, about 12%Based on disclosed samples of 60 life insurers and 79 non-life insurers.
• Companies with SARMRA between 70 and 7534 companies, about 24%Reflects relatively weak risk governance capabilities among many small and mid-sized insurers.
• Preferred regional bank nameBank of NingboThe report favors its FY26 fee-income growth potential and stable asset quality.

Impact & implications

The investment implication is that valuation divergence in the insurance sector may widen further. Large insurers with ample capital, strong distribution capabilities, solid risk governance, and clear dividend pathways are more attractive investments; small and mid-sized insurers with weak capital, insufficient internal profitability, and limited disclosure may be assigned higher risk premiums. China Taiping may capture natural business migration, while China Re may benefit from increased reinsurance demand driven by solvency pressure on small and mid-sized insurers.

Risks

• Smaller insurers’ capital replenishment capacity is weaker than expected, triggering more frequent capital calls.
• Motor insurance pricing pressure persists, widening underwriting losses in non-life insurance.
• Deterioration in SARMRA or IRR leads to regulatory restrictions on new business, distribution channels, or investment activities.
• Bancassurance channel reform further weakens new business acquisition capabilities of small and mid-sized insurers.
• Macroeconomic and capital market volatility drags on investment returns, solvency, and dividend visibility.
• Regional bank asset quality or capital pressure rises, leading to weaker risk appetite for the sector.

What to watch

• Changes in the distribution of core solvency ratios for life and non-life insurers after 2026.
• The number of insurers with SARMRA scores below 80, especially below 70.
• Whether the number of insurers with IRR ratings of C or D increases.
• The impact of bancassurance commission reform on new business growth at small and mid-sized insurers.
• Cases of capital replenishment, shareholder restructuring, M&A, or exit among small and mid-sized insurers.
• China Taiping’s new business migration and participating insurance operating performance.
• Changes in China Re’s reinsurance demand and regulatory rules.
• Bank of Ningbo’s FY26 fee income and asset quality stability.